“Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials ” (2024) SKIN The Journal of Cutaneous Medicine, 8(2), p. s375. doi:10.25251/skin.8.supp.375.